ArticleNature communications2016
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
18.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 1 synthesis or guideline pooled it, 291 citations in OpenAlex.
- Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.Nature medicine · 2022Pooled it
- Trial
- Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center.Blood cancer journal · 2021Trial
- Clinical and molecular characteristics ofHaematologica · 2019Trial
- Trial
- Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.Blood · 2017Trial
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Article
- Hsa_circ_0013729 Promotes Gastric Cancer Progression by Regulating MEF2D in ceRNA- and RBP- Dependent Manners.Biochemical genetics · 2026Article
- TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia.Science advances · 2026Article
- hnRNPUL1 has a dead polynucleotide kinase domain that regulates RNA and protein interactions.iScience · 2026Article
- The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions.Annals of hematology · 2026Article
- Expanding the spectrum of non-canonical NUT carcinoma: clinicopathological and molecular characterization ofFrontiers in oncology · 2026Article
- Distribution of molecular subtypes in a Colombian cohort of patients with acute lymphoblastic leukemia using whole-transcriptome analysis.Frontiers in oncology · 2026Article
- PD-1 Expression Promotes Immune Evasion in B-ALL.Hematology reports · 2025Article
- The Silent Revolution of the Genome: The Role of Optical Genome Mapping in Acute Lymphoblastic Leukemia.Cancers · 2025Review
- Palmitoylation modulates antitumor immunity.Molecular biology reports · 2025Review
- CABIN1 peptide effectively targets MEF2D-fusion protein in B-cell precursor acute lymphoblastic leukemia.Signal transduction and targeted therapy · 2025Article
- Article
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.Signal transduction and targeted therapy · 2025Article
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors at 20 institutions in 5 countries.
Zhaohui GuDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.
Michelle ChurchmanDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.
Kathryn RobertsDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.
Yongjin LiDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Yu LiuDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Richard C HarveyUniversity of New Mexico Cancer Center, Albuquerque, New Mexico 87106, USA.
Kelly McCastlainDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.ORCID 0000-0001-7868-3049
Shalini C ReshmiThe Research Institute, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
Debbie Payne-TurnerDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.
Ilaria IacobucciDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.
Ying ShaoDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.
I-Ming ChenUniversity of New Mexico Cancer Center, Albuquerque, New Mexico 87106, USA.
Marcus ValentineCytogenetic Shared Resource, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Deqing PeiDepartment of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee 38105.
Karen L MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.ORCID 0000-0002-0905-2742
Yussanne MaCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Richard MooreCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Marco MarraCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Eileen StonerockDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
Julie M Gastier-FosterDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
Meenakshi DevidasDepartment of Biostatistics, Colleges of Medicine and Public Health &Health Professions, University of Florida, Gainesville, Florida 32611, USA.
Yunfeng DaiDepartment of Biostatistics, Colleges of Medicine and Public Health &Health Professions, University of Florida, Gainesville, Florida 32611, USA.
Brent WoodDepartment of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA.
Michael BorowitzDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
Eric E LarsenMaine Children's Cancer Program, Scarborough, Maine 04074, USA.
Kelly MaloneyPediatric Hematology/Oncology/BMT, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado 80045, USA.
Leonard A MattanoHARP Pharma Consulting, Mystic, Connecticut 06355, USA.
Anne AngiolilloChildren's National Medical Center, Washington, DC 20010, USA.
Wanda L SalzerUS Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702, USA.ORCID 0000-0002-7820-9635
Michael J BurkeMedical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
Francesca GianniDepartment of Hematology and Bone Marrow Transplantation, Papa Giovanni XXIII Hospital Piazza OMS 1 24127, Bergamo, Italy.
Orietta SpinelliDepartment of Hematology and Bone Marrow Transplantation, Papa Giovanni XXIII Hospital Piazza OMS 1 24127, Bergamo, Italy.
Jerald P RadichFred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Anthony V MoormanLeukemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Bella PatelDepartment of Haemato-Oncology, Barts Cancer Institute, London EC1M 6BQ, UK.
Adele K FieldingDepartment of Hematology, UCL Cancer Institute, London WC1E 6BT, UK.
Jacob M RoweHematology, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Selina M LugerAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Ravi BhatiaDivision of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Ibrahim AldossDivision of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Stephen J FormanGehr Family Center for Leukemia Research, City of Hope, Duarte, California 91010, USA.
Jessica KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Guido MarcucciGehr Family Center for Leukemia Research, City of Hope, Duarte, California 91010, USA.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Wendy StockUniversity of Chicago Medical Center, Chicago, Illinois 60637, USA.
Steven KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Elisabeth PaiettaCancer Center, Montefiore Medical Center North Division, Bronx, New York 10467, USA.
Cheryl L WillmanUniversity of New Mexico Cancer Center, Albuquerque, New Mexico 87106, USA.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital, San Francisco, California 94158, USA.
Stephen P HungerChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Charles G MullighanDepartment of Pathology and Hematological Malignancies Program, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 342, Memphis, Tennessee 38105, USA.ORCID 0000-0002-1871-1850
St. Jude Children's Research Hospital · USBC Cancer Agency · CANationwide Children's Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of New Mexico · USCity of Hope · USOspedale Papa Giovanni XXIII · ITThe Ohio State University · USUniversity of Alabama at Birmingham · USUniversity of Florida Health · USAlliance for Clinical Trials in Oncology · USBridge Pharma (United States) · USCancer Research UK · GBChildren's Hospital Colorado · USChildren's Hospital of Philadelphia · USChildren's National · USFred Hutch Cancer Center · USInstitute of Cancer Research · GBJohns Hopkins University · USMedical College of Wisconsin · US
Funding
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MECOG Specimen BankingU24CA114737 · NCI · FRONTIER SCI &TECHNOLOGY RSCH FDN, INC · PI COMIS, ROBERT L · 2005 to 2014
$9.3MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MCancer Research UK 21019CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA021765NCI NIH HHS RC1 CA145707NCI NIH HHS U01 CA157937NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180861NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114737NCI NIH HHS U24 CA114766NCI NIH HHS U24 CA196171NCI NIH HHS U24 CA196172NIGMS NIH HHS P50 GM115279
Abstract
Chromosomal rearrangements are initiating events in acute lymphoblastic leukaemia (ALL). Here using RNA sequencing of 560 ALL cases, we identify rearrangements between MEF2D (myocyte enhancer factor 2D) and five genes (BCL9, CSF1R, DAZAP1, HNRNPUL1 and SS18) in 22 B progenitor ALL (B-ALL) cases with a distinct gene expression profile, the most common of which is MEF2D-BCL9. Examination of an extended cohort of 1,164 B-ALL cases identified 30 cases with MEF2D rearrangements, which include an additional fusion partner, FOXJ2; thus, MEF2D-rearranged cases comprise 5.3% of cases lacking recurring alterations. MEF2D-rearranged ALL is characterized by a distinct immunophenotype, DNA copy number alterations at the rearrangement sites, older diagnosis age and poor outcome. The rearrangements result in enhanced MEF2D transcriptional activity, lymphoid transformation, activation of HDAC9 expression and sensitive to histone deacetylase inhibitor treatment. Thus, MEF2D-rearranged ALL represents a distinct form of high-risk leukaemia, for which new therapeutic approaches should be considered.
Indexed as
AnimalsBase SequenceGene Expression Regulation, LeukemicGene RearrangementGenomicsHistone Deacetylase InhibitorsHumansLuciferasesMEF2 Transcription FactorsMiceNIH 3T3 CellsOncogene Proteins, FusionPrecursor Cell Lymphoblastic Leukemia-LymphomaSequence Analysis, RNATranscriptomeTreatment OutcomeHistone Deacetylase InhibitorsLuciferasesMEF2D protein, humanMEF2 Transcription FactorsOncogene Proteins, Fusion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.